# Veeco Instruments Inc: Form 10-Q for the period ended Mar 31, 2023

- Company: [Veeco Instruments Inc](/companies/veco.md) (CIK 103145)
- Form: 10-Q
- Filed: 2023-05-08
- Accepted by EDGAR: May 8, 2023, 16:30 ET
- Period: 2023-03-31
- Accession: 0001558370-23-008539
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/103145/000155837023008539/veco-20230331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/103145/000155837023008539/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $153.5m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $91.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $62.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-01-01 to 2023-03-31 | $27.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2023-01-01 to 2023-03-31 | $22.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | $9.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-01-01 to 2023-03-31 | $2.9m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | $263.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | $8.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 59,856,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2023-01-01 to 2023-03-31 | $13.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-01-01 to 2023-03-31 | $6.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-03-31 | $140.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $643.3m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $1.17bn | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $267.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $581.7m | us-gaap:Liabilities |
| Long-term debt | at 2023-03-31 | $254.7m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2023-03-31 | $585.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 22,712 characters.

### Cautionary Statement Regarding Forward Looking Statements

Our discussion below constitutes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this Report, the words “believes,” “anticipates,” “expects,” “estimates,” “targets,” “plans,” “intends,” “will,” and similar expressions related to the future are intended to identify forward-looking statements. All forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from projected results. You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made.

### Executive Summary

We are an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, MOCVD, CVD, and single wafer etch & clean technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco’s systems and service offerings, visit www.veeco.com.

### Business Update

Macroeconomic challenges across the industry have been well publicized, including supply chain constraints, an inflationary and high-interest rate environment with a potential recession ahead, new China-export regulations, uncertainty in the banking industry, and a forecasted decline in the semiconductor and related markets due to softness in consumer, smartphone and PC applications, all of which are contributing to a difficult environment with increased uncertainty.

Longer lead times and parts shortages and allocations have required that we plan further ahead than usual, and we have undertaken efforts to increase our purchase commitments to secure critical components in a timely manner. Although on time deliveries by suppliers have improved, material lead times remain elevated and continue to be a challenge with respect to our supply chain, limiting our ability to fulfill some of our customers’ demands in a timely manner, as many of our peers have also been experiencing. Although we are seeing some signs that lead times could improve in the second half of the year, we expect supply shortages and related challenges to persist throughout 2023, and we continue to monitor our supply chain and work with our suppliers to identify and mitigate potential gaps in an effort to ensure continuity of supply. We also continue to experience increasing labor, logistics, and material costs, creating gross margin pressures.

We have seen a slow-down in certain shorter lead time products such as wet processing, advanced packaging lithography, and spare parts and upgrades, as well as instances where customers have requested order cancellations, delayed shipments, or delayed payments. Consequently, we are monitoring the situation very closely and have been taking early actions to limit the pace at which we increase spending while maintaining our growth trajectory.

Furthermore, the US Department of Commerce, Bureau of Industry and Security (“BIS”), issued China-export regulations on October 7, 2022 which broadened the requirements under which export licenses will be required, with a presumption of denial as to their issuance. In addition, certain China-based companies were added to the BIS Unverified List, and changes have been made to the BIS Entity List, further restricting sales to the named entities. Recent order activity has led to significant backlog in China, some of which may be subject to these regulations. While the export regulation landscape is fluid and evolving, we believe at this time that the substantial majority of this backlog will not be negatively affected by the new regulations. We anticipate our order backlog for China customers to decline in the second half of 2023 as we deliver these systems in the first half of the year.

While we work to overcome these macroeconomic challenges, we continue to serve our customers in the following four end-markets: Semiconductor; Compound Semiconductor; Data Storage; and Scientific & Other.

Sales in the Semiconductor market grew 20% year-over-year and declined 1% sequentially in Q1 2023 driven by our laser annealing systems for trailing node logic devices. We continue to build momentum for our laser annealing solutions at advanced node logic customers by winning application steps. We recently announced the receipt of multiple orders for our LSA systems that are qualified for advanced nodes for a Tier 1 logic supplier. While our growth strategy is predominately focused on shipping systems for advanced node logic and memory applications we have also been receiving orders and shipping systems for trailing node applications in China and other regions. In memory we introduced laser annealing to the market and have leveraged a successful evaluation at a DRAM manufacturer into recently placed multiple orders for high volume production of DRAM devices. The ongoing adoption of EUV Lithography for advanced node semiconductor manufacturing continues to drive demand for our Ion Beam mask blank systems. Additionally, our lithography systems for Advanced Packaging are aligned with packaging approaches such as fan out wafer level packaging and other advanced packaging applications, while our wet processing systems are used for Photo Resist Strip and Solvent Cleans. We are currently seeing softness in our Advanced Packaging Lithography and wet processing businesses due to declining consumer electronics demand. Overall, our technology and market strategy are well aligned with trends such as artificial intelligence, mobile connectivity and high-performance computing that drive the Semiconductor market. Given recent order activity and current backlog in the Semiconductor market, we expect revenue in 2023 to outpace wafer fab equipment spending growth, which is the prevailing consensus view has forecasted to be down 15-25% or more in 2023.

We address the Compound Semiconductor market with a broad portfolio of technologies, including Wet Processing and MOCVD, along with MBE and Ion Beam, all of which have been developed to support emerging applications such as 5G driven RF device/filter manufacturing, GaN power electronics, and photonics applications including edge-emitting lasers, specialty LEDs and micro-LEDs. Sales in the Compound Semiconductor market in Q1 2023 declined as compared to the prior quarter and comparable prior quarter. In Q1 2023, we shipped systems for photonics applications. We continue to invest for future growth in the Compound Semiconductor market in areas like power electronics and Micro-LEDs. Power electronics markets are served by GaN equipment, and also by SiC epitaxy equipment. We are working to penetrate the GaN power market, which is driven by applications such as wireless charging in consumer electronics. In addition to our GaN system offerings, on January 31st, 2023 Veeco acquired SiC technology to address the high-growth SiC power epitaxy equipment market, which is driven by electric vehicles. With this acquisition, Veeco is accelerating its entry into this market, and expects revenue starting in 2024.

Sales in the Data Storage market in Q1 2023 increased from prior quarter while remaining flat quarter over comparable prior year period. Demand for our Ion Beam products is driven by cloud-based storage. Hard disk drive manufacturers are manufacturing drives with an increasing number of magnetic heads and they are introducing advanced technologies which require increased capital intensity. With data proliferation forecasted to continue to grow, and based on orders we received in 2022 and into 2023, we expect revenue growth in 2023.

Sales in the Scientific & Other market are largely driven by sales to governments, universities, and research institutions. We address the Scientific & Other market with several technologies, including MBE, ALD, MOCVD, Wet Processing, & IBD/IBE, which support scientific, optical coating and other applications, such as Micro-Electromechanical Systems (MEMS) applications. While revenue was down year-over-year and from the prior quarter, we expect sales in this market to grow in the long run, in line with GDP.

Overall, based on our current visibility supported by our backlog, we continue to expect total 2023 revenue to be in the range of $630 million to $670 million.

### Results of Operations

### For the three months ended March 31, 2023 and 2022

The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the indicated periods in 2023 and 2022 and the period-over-period dollar and percentage changes for those line items. Our results of operations are reported as one business segment, represented by our single operating segment.

*(dollars in thousands)*

| ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ Three Months Ended March 31, 2023 | ​ ​ | ​ ​ | ​ ​ | ​ ​ 2022 | ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ Change Period to Period | ​ ​ | ​ | ​ ​ ​ ​ |
| --- | --- | ---: | ---: | --- | --- | ---: | ---: | --- | --- | ---: | ---: | --- | --- |
| Net sales |  | $153,504 | 100% | ​ | ​ | $156,426 | 100% | ​ | ​ | $(2,922) | (2)% | ​ |  |
| Cost of sales | ​ | 91,487 | 60% | ​ | ​ | 90,413 | 58% | ​ | ​ | 1,074 | 1% | ​ | ​ |
| Gross profit | ​ | 62,017 | 40% | ​ | ​ | 66,013 | 42% | ​ | ​ | (3,996) | (6)% | ​ | ​ |
| Operating expenses, net: | ​ |  |  | ​ | ​ |  | ​ | ​ | ​ |  | ​ | ​ | ​ |
| Research and development | ​ | 27,562 | 18% | ​ | ​ | 24,117 | 15% | ​ | ​ | 3,445 | 14% | ​ | ​ |
| Selling, general, and administrative | ​ | 22,627 | 15% | ​ | ​ | 22,894 | 15% | ​ | ​ | (267) | (1)% | ​ | ​ |
| Amortization of intangible assets | ​ | 2,111 | 1% | ​ | ​ | 2,504 | 2% | ​ | ​ | (393) | (16)% | ​ | ​ |
| Other operating expense (income), net | ​ | (89) | - | ​ | ​ | (19) | - | ​ | ​ | (70) | \* | ​ | ​ |
| Total operating expenses, net | ​ | 52,211 | 34% | ​ | ​ | 49,496 | 32% | ​ | ​ | 2,715 | 5% | ​ | ​ |
| Operating income | ​ | 9,806 | 6% | ​ | ​ | 16,517 | 11% | ​ | ​ | (6,711) | (41)% | ​ | ​ |
| Interest income (expense), net | ​ | (802) | (1)% | ​ | ​ | (2,803) | (2)% | ​ | ​ | 2,001 | (71)% | ​ | ​ |
| Income before income taxes | ​ | 9,004 | 6% | ​ | ​ | 13,714 | 9% | ​ | ​ | (4,710) | (34)% | ​ | ​ |
| Income tax expense (benefit) | ​ | 263 | - | ​ | ​ | 384 | - | ​ | ​ | (121) | (32)% | ​ | ​ |
| Net income | ​ | $8,741 | 6% | ​ | ​ | $13,330 | 9% | ​ | ​ | $(4,589) | (34)% | ​ | ​ |

\* Not meaningful

#### Net Sales

The following is an analysis of sales by market and by region:

*(dollars in thousands)*

| ​ ​ ​ ​ Sales by end-market | ​ ​ ​ ​ | ​ ​ Three Months Ended March 31, 2023 ​ | ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ 2022 ​ | ​ | ​ | ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ Change Period to Period ​ | ​ ​ | ​ ​ | ​ ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | --- | ---: | --- | ---: | --- | --- | ---: | ---: | --- | --- |
| Semiconductor | ​ | $93,107 |  | 60% | ​ | ​ | $77,620 |  | 49% | ​ | ​ | $15,487 | 20% | ​ | ​ |
| Compound Semiconductor | ​ | 21,159 |  | 14% | ​ | ​ | 37,109 |  | 24% | ​ | ​ | (15,950) | (43)% | ​ | ​ |
| Data Storage | ​ | 21,514 |  | 14% | ​ | ​ | 21,595 |  | 14% | ​ | ​ | (81) | (0)% | ​ | ​ |
| Scientific & Other | ​ | 17,724 |  | 12% | ​ | ​ | 20,102 |  | 13% | ​ | ​ | (2,378) | (12)% | ​ | ​ |
| **Total** | ​ | $153,504 |  | 100% | ​ | ​ | $156,426 |  | 100% | ​ | ​ | $(2,922) | (2)% | ​ | ​ |
| **Sales by geographic region** | ​ |  |  |  | ​ | ​ |  |  |  | ​ | ​ |  | ​ | ​ | ​ |
| United States | ​ | $31,011 |  | 20% | ​ | ​ | $47,471 |  | 30% | ​ | ​ | $(16,460) | (35)% | ​ | ​ |
| EMEA | ​ | 22,947 |  | 15% | ​ | ​ | 21,425 |  | 14% | ​ | ​ | 1,522 | 7% | ​ | ​ |
| China | ​ | ​ 60,747 | ​ | 40% | ​ | ​ | ​ 30,381 | ​ | 19% | ​ | ​ | ​ 30,366 | 100% | ​ | ​ |
| Rest of APAC | ​ | 38,744 |  | 25% | ​ | ​ | 56,922 |  | 37% | ​ | ​ | (18,178) | (32)% | ​ | ​ |
| Rest of World | ​ | 54 |  | - | ​ | ​ | 227 |  | - | ​ | ​ | (173) | \* | ​ | ​ |
| **Total** | ​ | $153,504 |  | 100% | ​ | ​ | $156,426 |  | 100% | ​ | ​ | $(2,922) | (2)% | ​ | ​ |

\* Not meaningful

Sales decreased for the three months ended March 31, 2023 against the comparable prior year period in the Compound Semiconductor and Scientific & Other markets, partially offset by an increase in the Semiconductor market. By geography, sales increased in the China and EMEA regions. Sales in the Rest of APAC region for the three months ended March 31, 2023 included sales in Taiwan and Thailand of $18.0 million and $8.4 million respectively. Sales in the Rest of APAC region for the three months ended March 31, 2022 included sales in Singapore and Taiwan of $23.9 million and $17.2 million, respectively. We expect there will continue to be year-to-year variations in our future sales distribution across markets and geographies. In light of the global nature of our business, we are impacted by conditions in the various countries in which we and our customers operate.

#### Gross Profit

For the three months ended March 31, 2023, gross profit decreased against the comparable prior period due to a decrease in sales volume and gross margins. Gross margins decreased principally due to product mix of sales in the period, as well as increased logistics costs, partially offset by favorable operations spend activity. We expect our gross margins to fluctuate each period due to product mix and other factors.

#### Research and Development

The markets we serve are characterized by continuous technological development and product innovation, and we invest in various research and development initiatives to maintain our competitive advantage and achieve our growth objectives. Research and development expenses increased for the three months ended March 31, 2023 against the comparable prior period primarily due to personnel-related expenses as we invest in new research and development and additional applications for our technology in order to be well-positioned to capitalize on emerging global megatrends and support longer term growth in Semiconductor and Compound Semiconductor markets.

#### Selling, General, and Administrative

Selling, general, and administrative expenses remained flat for the three months ended March 31, 2023 against the comparable prior period. Given the uncertainty regarding the impacts on our business resulting from the general macroeconomic environment, we are focused on the proactive management of expenses.

#### Amortization Expense

Amortization expense decreased compared to the comparable prior year period primarily due to changes in amortization expense to reflect expected cash flows of certain intangible assets.

#### Interest Income (Expense)

We recorded net interest expense of $0.8 million for the three months ended March 31, 2023, compared to $2.8 million for the comparable prior year period. The decrease in net interest expense was primarily related to an increase of interest income of approximately $2.0 million due to a more favorable interest rate environment for the three months ended March 31, 2023, against the comparable prior year period.

#### Income Taxes

At the end of each interim reporting period, we estimate the effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.

Our tax expense for the three months ended March 31, 2023, was $0.3 million, compared to $0.4 million for the period ended March 31, 2022. For the three months ended March 31, 2023, the effective tax rate was lower than the U.S. statutory tax rate primarily relating to a discrete income tax benefit for share-based compensation windfall. Additionally, the effective tax rate was also favorably impacted by the tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. For the three months ended March 31, 2022, the effective tax rate was lower than the U.S. statutory tax rate primarily related to changes in the valuation allowance of deferred tax assets in the U.S.

### Liquidity and Capital Resources

Our cash and cash equivalents, restricted cash, and short-term investments are as follows:

*(in thousands)*

| ​ ​ ​ ​ | ​ ​ ​ | ​ ​ March 31, 2023 | ​ ​ | ​ ​ December 31, 2022 |
| --- | --- | ---: | --- | ---: |
| Cash and cash equivalents | ​ | $140,721 | ​ | $154,925 |
| Restricted cash | ​ | 476 | ​ | 547 |
| Short-term investments | ​ | 112,170 | ​ | 147,488 |
| **Total** | ​ | $253,367 | ​ | $302,960 |

At March 31, 2023 and December 31, 2022, cash and cash equivalents of $30.9 million and $28.4 million, respectively, were held outside the United States. As of March 31, 2023, we had $18.7 million of accumulated undistributed earnings generated by our non-U.S. subsidiaries for which the U.S. tax has previously been provided. Approximately $8.1 million of undistributed earnings will be subject to foreign withholding taxes if distributed back to the United States and we accrued $0.9 million for foreign withholding taxes for the undistributed earnings.

We believe that our projected cash flow from operations, combined with our cash and short-term investments, will be sufficient to meet our projected working capital requirements, contractual obligations, and other cash flow needs for the next twelve months, including scheduled interest payments on our convertible senior notes, purchase commitments, and payments in respect of operating leases.

A summary of the cash flow activity for the three months ended March 31, 2023 and 2022 is as follows:

#### Cash Flows from Operating Activities

*(in thousands)*

| ​ ​ ​ ​ | ​ ​ ​ | ​ ​ Three Months Ended March 31, 2023 | ​ | ​ ​ 2022 | ​ ​ |
| --- | --- | ---: | --- | ---: | --- |
| Net income | ​ | $8,741 | ​ | $13,330 | ​ |
| Non-cash items: | ​ | ​ ​ | ​ | ​ ​ | ​ |
| Depreciation and amortization | ​ | 6,276 | ​ | 6,240 | ​ |
| Non-cash interest expense | ​ | 226 | ​ | 238 | ​ |
| Deferred income taxes | ​ | 191 | ​ | (16) | ​ |
| Share-based compensation expense | ​ | 7,027 | ​ | 4,481 | ​ |
| Changes in operating assets and liabilities | ​ | (8,543) | ​ | 515 | ​ |
| **Net cash provided by (used in) operating activities** | ​ | $13,918 | ​ | $24,788 | ​ |

Net cash provided by operating activities was $13.9 million for the three months ended March 31, 2023 and was due to net income of $8.7 million and adjustments for non-cash items of $13.7 million, partially offset by a decrease in cash flow from changes in operating assets and liabilities of $8.5 million. The changes in operating assets and liabilities were largely attributable to 1) increases in inventories; partially offset by 2) increases in accounts payable and accrued expenses; and 3) increases in customer deposits and deferred revenue.

#### Cash Flows from Investing Activities

*(in thousands)*

| ​ ​ ​ ​ | ​ ​ ​ | ​ ​ Three Months Ended March 31, 2023 | ​ | ​ ​ 2022 | ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- |
| Acquisitions of businesses, net of cash acquired | ​ | $(30,373) | ​ | $— | ​ |
| Capital expenditures | ​ | $(6,946) | ​ | $(10,918) | ​ |
| Changes in investments, net | ​ | 36,557 | ​ | (238) | ​ |
| **Net cash provided by (used in) investing activities** | ​ | $(762) | ​ | $(11,156) | ​ |

The cash used in investing activities during the three months ended March 31, 2023 and 2022 was primarily attributable to the net cash used in the acquisition of Epiluvac, as well as capital expenditures, partially offset by net investment activity. We experienced a high level of capital expenditures during 2022 associated with the continued build-out of our newly leased facility in San Jose, California, which is substantially complete at this time.

#### Cash Flows from Financing Activities

*(in thousands)*

| ​ ​ ​ ​ | ​ ​ ​ | ​ ​ Three Months Ended March 31, 2023 | ​ | ​ ​ 2022 | ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- |
| Repayment of 2023 Notes | ​ | $(20,173) | ​ | ​ — | ​ |
| Settlement of equity awards, net of withholding taxes | ​ | ​ (7,268) | ​ | $(5,789) | ​ |
| **Net cash provided by (used in) financing activities** | ​ | $(27,441) | ​ | $(5,789) | ​ |

The cash used in financing activities for the three months ended March 31, 2023 was related to the repayment of the 2023 Notes, as well as cash used to settle taxes related to employee equity programs, partially offset by cash received under the Employee Stock Purchase Plan.

#### Convertible Senior Notes

We have $132.5 million outstanding principal balance of 3.50% convertible senior notes that bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, and mature on January 15, 2025, unless earlier purchased by the Company, redeemed, or converted. In addition, we have $125.0 million outstanding principal balance of 3.75% convertible senior notes that bear interest at a rate of 3.75% per year, payable semiannually in arrears on June 1 and December 1 of each year, and mature on June 1, 2027, unless earlier purchased by the Company, redeemed, or converted. The 2027 Notes are currently convertible by shareholders until June 30, 2023.

We believe that we have sufficient capital resources and cash flows from operations to support scheduled interest payments on these debts. In addition, we have access to a $150.0 million revolving credit facility (including an ability to request an additional $75.0 million, for a total commitment of no more than $225.0 million) to provide for our working capital needs and reimburse drawings under letters of credit and for other general corporate purposes. The Company has no immediate plans to draw down on the facility, which expires in December of 2026. Interest under the facility is variable based on the Company’s secured net leverage ratio and is expected to bear interest based on SOFR plus a range of 150 to 225 basis points, if drawn. There is a yearly commitment fee of 25 to 35 basis points, based on the Company’s secured net leverage ratio, charged on the unused portion of the Facility.

#### Contractual Obligations and Commitments

We have commitments under certain contractual arrangements to make future payments for goods and services. These contractual arrangements secure the rights to various assets and services to be used in the future in the normal course of business. We expect to fund these contractual arrangements with cash generated from operations in the normal course of business.

## Market risk

As filed, 2,942 characters.

#### Interest Rate Risk

Our exposure to market rate risk for changes in interest rates primarily relates to our investment portfolio. We centrally manage our investment portfolios considering investment opportunities and risks, tax consequences, and overall financing strategies. Our investment portfolio includes fixed-income securities with a fair value of approximately $112.2 million at March 31, 2023. These securities are subject to interest rate risk and, based on our investment portfolio at March 31, 2023, a 100 basis point increase in interest rates would result in a decrease in the fair value of the portfolio of $0.4 million. While an increase in interest rates may reduce the fair value of the investment portfolio, we will not realize the losses in the Consolidated Statements of Operations unless the individual fixed-income securities are sold prior to recovery or the loss is determined to be other-than-temporary.

#### Currency Exchange Risk

We conduct business on a worldwide basis and, as such, a portion of our revenues, earnings, and net investments in foreign affiliates is exposed to changes in currency exchange rates. The economic impact of currency exchange rate movements is complex because such changes are often linked to variability in real growth, inflation, interest rates, governmental actions, and other factors. These changes, if material, could cause us to adjust our financing and operating strategies. Consequently, isolating the effect of changes in currency does not incorporate these other important economic factors.

Changes in currency exchange rates could affect our foreign currency denominated monetary assets and liabilities and forecasted cash flows. We may enter into monthly forward derivative contracts from time to time with the intent of mitigating a portion of this risk. We only use derivative financial instruments in the context of hedging and not for speculative purposes and have not historically designated our foreign exchange derivatives as hedges. Accordingly, changes in fair value from these contracts are recorded as “Other, net” in our Consolidated Statements of Operations. We execute derivative transactions with highly rated financial institutions to mitigate counterparty risk.

Our net sales to customers located outside of the United States represented approximately 80% and 70% of our total net sales for the three months ended March 31, 2023 and 2022, respectively. We expect that net sales to customers outside the United States will continue to represent a large percentage of our total net sales. Our sales denominated in currencies other than the U.S. dollar represented approximately 3% of total net sales for both the three months ended March 31, 2023 and 2022.

A 10% change in foreign exchange rates would have an immaterial impact on the consolidated results of operations since most of our sales outside the United States are denominated in U.S. dollars.

## Controls and procedures

As filed, 1,373 characters.

#### Evaluation of Disclosure Controls and Procedures

Our principal executive and financial officers have evaluated and concluded that our disclosure controls and procedures are effective as of March 31, 2023. The disclosure controls and procedures are designed to ensure that the information required to be disclosed in this report filed under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to our principal executive and financial officers as appropriate to allow timely decisions regarding required disclosure.

#### Changes in Internal Control Over Financial Reporting

On January 31, 2023, we completed the acquisition of Epiluvac AB and are integrating the acquired business into our overall internal control over financial reporting process. Management is in the process of assessing the internal control over financial reporting and is implementing or revising internal controls where necessary. See Note 3 to the

Consolidated Financial Statements – *Business Combinations*, for further details. There were no other changes in internal control for the quarter ended March 31, 2023 that have materially affected or are reasonably likely to materially affect internal control over financial reporting.

## Risk factors

As filed, 250 characters.

Information regarding risk factors appears in the Safe Harbor Statement at the beginning of this quarterly report on Form 10-Q, in Part I — Item 1A of our 2022 Form 10-K. There have been no material changes from the risk factors previously disclosed,

Filed May 8, 2023.
Source: SEC EDGAR, the filing index for accession 0001558370-23-008539. Last ingested by Listed: Nov 11, 2026, 01:48 ET. No prices; not investment advice.
